SOTERA HEALTH COMPANY Operating Expenses
SOTERA HEALTH COMPANY (SHC) reported Operating Expenses of $304.67 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2025-02-27
- SOTERA HEALTH COMPANY operating expenses for the quarter ending 2024-12-31 was $77.22M, a 1.53% increase year-over-year.
- SOTERA HEALTH COMPANY operating expenses for the quarter ending 2024-09-30 was $77.52M, a 10.92% increase year-over-year.
- SOTERA HEALTH COMPANY operating expenses for the quarter ending 2024-06-30 was $75.99M, a 0.51% decline year-over-year.
- SOTERA HEALTH COMPANY operating expenses for the quarter ending 2024-03-31 was $73.94M, a 5.37% decline year-over-year.
- SOTERA HEALTH COMPANY operating expenses for fiscal 2024 was $304.67M, a 1.40% increase from fiscal 2023.
- SOTERA HEALTH COMPANY operating expenses for fiscal 2023 was $300.47M, a 2.65% decline from fiscal 2022.
- SOTERA HEALTH COMPANY operating expenses for fiscal 2022 was $308.65M, a 17.83% increase from fiscal 2021.
- SOTERA HEALTH COMPANY operating expenses for fiscal 2021 was $261.94M, a 10.27% increase from fiscal 2020.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2024-12-31 | $77.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $154.74M derived: sum of 2 quarters · filed 2025-02-27 | $230.73M derived: sum of 3 quarters · filed 2025-02-27 | $304.67M 10-K · filed 2025-02-27 |
| 2024-09-30 | $77.52M 10-Q · filed 2024-11-05 | $153.51M derived: sum of 2 quarters · filed 2024-11-05 | $227.45M 10-Q · filed 2024-11-05 | $303.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | $75.99M 10-Q · filed 2024-08-05 | $149.93M 10-Q · filed 2024-08-05 | $225.99M derived: sum of 3 quarters · filed 2025-02-27 | $295.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $73.94M 10-Q · filed 2024-05-02 | $150.00M derived: sum of 2 quarters · filed 2025-02-27 | $219.89M derived: sum of 3 quarters · filed 2025-02-27 | $296.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $76.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $145.94M derived: sum of 2 quarters · filed 2025-02-27 | $222.33M derived: sum of 3 quarters · filed 2025-02-27 | $300.47M 10-K · filed 2025-02-27 |
| 2023-09-30 | $69.89M 10-Q · filed 2024-11-05 | $146.27M derived: sum of 2 quarters · filed 2024-11-05 | $224.41M 10-Q · filed 2024-11-05 | $305.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $76.38M 10-Q · filed 2024-08-05 | $154.52M 10-Q · filed 2024-08-05 | $236.07M derived: sum of 3 quarters · filed 2025-02-27 | $308.89M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $78.14M 10-Q · filed 2024-05-02 | $159.69M derived: sum of 2 quarters · filed 2025-02-27 | $232.51M derived: sum of 3 quarters · filed 2025-02-27 | $311.41M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $81.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $154.37M derived: sum of 2 quarters · filed 2025-02-27 | $233.27M derived: sum of 3 quarters · filed 2025-02-27 | $308.65M 10-K · filed 2025-02-27 |
| 2022-09-30 | $72.82M 10-Q · filed 2023-11-01 | $151.72M derived: sum of 2 quarters · filed 2023-11-01 | $227.10M 10-Q · filed 2023-11-01 | $294.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $78.90M 10-Q · filed 2023-08-03 | $154.28M 10-Q · filed 2023-08-03 | $221.81M derived: sum of 3 quarters · filed 2024-02-27 | $281.73M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $75.38M 10-Q · filed 2023-05-03 | $142.91M derived: sum of 2 quarters · filed 2024-02-27 | $202.82M derived: sum of 3 quarters · filed 2024-02-27 | $268.31M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $67.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $127.44M derived: sum of 2 quarters · filed 2024-02-27 | $192.93M derived: sum of 3 quarters · filed 2024-02-27 | $261.94M 10-K · filed 2024-02-27 |
| 2021-09-30 | $59.91M 10-Q · filed 2022-11-02 | $125.40M derived: sum of 2 quarters · filed 2022-11-02 | $194.41M 10-Q · filed 2022-11-02 | $262.61M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $65.49M 10-Q · filed 2022-08-04 | $134.50M 10-Q · filed 2022-08-04 | $202.69M derived: sum of 3 quarters · filed 2023-02-28 | $263.17M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $69.01M 10-Q · filed 2022-05-05 | $137.20M derived: sum of 2 quarters · filed 2023-02-28 | $197.69M derived: sum of 3 quarters · filed 2023-02-28 | $254.91M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $68.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $128.68M derived: sum of 2 quarters · filed 2023-02-28 | $185.90M derived: sum of 3 quarters · filed 2023-02-28 | $237.55M 10-K · filed 2023-02-28 |
| 2020-09-30 | $60.48M 10-Q · filed 2021-11-10 | $117.71M derived: sum of 2 quarters · filed 2021-11-10 | $169.36M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $57.23M 10-Q · filed 2021-08-12 | $108.88M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $51.65M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $211.83M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |